PMID- 25944796
OWN - NLM
STAT- MEDLINE
DCOM- 20160121
LR  - 20221207
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 32
IP  - 6
DP  - 2015 Jun
TI  - A phase II clinical study of using nab-paclitaxel as second-line chemotherapy for 
      Chinese patients with advanced non-small cell lung cancer.
PG  - 498
LID - 10.1007/s12032-015-0498-x [doi]
AB  - The aim of this clinical study was to evaluate the efficacy and safety of 
      nab-paclitaxel to treat patients with advanced non-small cell lung cancer (NSCLC) 
      who failed first-line chemotherapy. Eligible patients had advanced NSCLC and had 
      been treated with first-line platinum-based chemotherapy but still had disease 
      progression. Patients received nab-paclitaxel 100 mg/m(2) (i.v.) on days 1, 8 and 
      15 of a 28-day cycle. Primary endpoint is 6-month progression-free survival 
      (PFS). Fifty-six patients with advanced NSCLC were enrolled in the study (55.4 % 
      male patients, 44.6 % female patients; median age 59.6 years; ranging from 32 to 
      83 years). Six-month PFS rate was 18 % (95 % CI 7.8-28.7 %). Median PFS was 3.5 
      months (95 % CI 1.9-5.8 months). Median overall survival was 6.8 months (95 % CI 
      4.7-9.3 months). No complete responses were achieved. Overall response rate was 
      16.1 % (95 % CI 8.9-24.7 %). Grade 3 or 4 adverse events (AEs) were observed in 
      patients receiving nab-paclitaxel. The most common grade 3 or 4 AEs were 
      dizziness, pulmonary embolism and fatigue. Nab-paclitaxel showed clinically 
      equivalent efficacy on patients' survivals and response rates, as compared with 
      other FDA-approved second-line chemotherapy agents. Given the tolerability on 
      grade 3 or 4 adverse events, nab-paclitaxel may be considered an alternative 
      second-line treatment option for NSCLC.
FAU - Hu, Wei
AU  - Hu W
AD  - Department of Oncology, Jining First People's Hospital, 6 Jiankang Road, Shi 
      Zhong Qu, Jining, 272011, Shandong, China.
FAU - Zhang, Zhiping
AU  - Zhang Z
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
DEP - 20150506
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
RN  - 0 (130-nm albumin-bound paclitaxel)
RN  - 0 (Albumins)
RN  - 0 (Antineoplastic Agents)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Albumins/*therapeutic use
MH  - Antineoplastic Agents/*therapeutic use
MH  - Asian People
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Paclitaxel/*therapeutic use
MH  - Treatment Outcome
EDAT- 2015/05/07 06:00
MHDA- 2016/01/23 06:00
CRDT- 2015/05/07 06:00
PHST- 2015/01/07 00:00 [received]
PHST- 2015/01/23 00:00 [accepted]
PHST- 2015/05/07 06:00 [entrez]
PHST- 2015/05/07 06:00 [pubmed]
PHST- 2016/01/23 06:00 [medline]
AID - 10.1007/s12032-015-0498-x [doi]
PST - ppublish
SO  - Med Oncol. 2015 Jun;32(6):498. doi: 10.1007/s12032-015-0498-x. Epub 2015 May 6.